Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.
CSPC Pharmaceutical Group has announced that its new drug, SYH2070 Injection, has received approval from China’s National Medical Products Administration for clinical trials. This siRNA drug, designed for liver-targeted delivery to reduce ANGPTL3 levels, shows promise in treating hypertriglyceridemia and mixed hyperlipidemia, with preclinical studies highlighting its superior pharmacological activity and long-lasting effects compared to similar products, potentially enhancing the company’s position in the pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company primarily deals with chemical drugs and has a market focus on creating treatments for various health conditions.
Average Trading Volume: 177,486,024
Technical Sentiment Signal: Buy
Current Market Cap: HK$104.6B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.